Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise [Seeking Alpha]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Seeking Alpha
Vopimetostat, the lead PRMT5 inhibitor, advances to a pivotal trial in 2L MTAP-deleted pancreatic cancer, with FDA-aligned design and robust enrollment. TNGX boasts a $343m cash position, partnerships with Gilead and Revolution Medicines, and multiple upcoming data catalysts, but faces fierce competition. With a $2.3bn market cap, TNGX must deliver strong clinical data to justify valuation; early-stage readouts in 2026 may not provide definitive answers. I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more. Learn More » master1305/iStock via Getty Images Investment Overview The stock of Tango Therapeutics, Inc. ( TNGX ) surged in value yesterday, rising from ~$12.4, to $17.4 per share, a gain of ~43%, as the Boston, Massachusetts based biotech reported its Q4 More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healt
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Tango Therapeutics (TNGX) had its price target raised by Wedbush from $15.00 to $19.00. They now have an "outperform" rating on the stock.MarketBeat
- Tango Therapeutics (TNGX) had its price target raised by Guggenheim from $18.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Tango Therapeutics (TNGX) had its price target raised by HC Wainwright from $13.00 to $27.00. They now have a "buy" rating on the stock.MarketBeat
TNGX
Earnings
- 3/5/26 - Beat
TNGX
Sec Filings
- 3/5/26 - Form 144
- 3/5/26 - Form S-8
- 3/5/26 - Form 8-K
- TNGX's page on the SEC website